Related Experiment Videos
Treating refractory epilepsy with tiagabine: clinical experience
1Department of Neurology, Middlesborough General Hospital, Middlesborough, UK. Paul.McKee@stees.nhs.uk
Seizure
|August 25, 2004
Summary
Tiagabine, a selective gamma-aminobutyric acid (GABA) re-uptake inhibitor, showed effectiveness in treating refractory epilepsy. This new anticonvulsant demonstrated a significant reduction in seizure frequency for many patients when used in combination therapy.
Area of Science:
- Neurology
- Pharmacology
Background:
- Epilepsy affects over 30% of patients refractory to standard treatments.
- Combination therapy offers a potential strategy for improved seizure control.
Purpose of the Study:
- To evaluate the efficacy and safety of tiagabine as an add-on therapy for patients with refractory epilepsy.
- To assess the optimal dosing strategy for tiagabine in this patient population.
Main Methods:
- An observational study involving 20 consecutive patients with refractory epilepsy.
- Tiagabine was administered at doses ranging from 20-40 mg/day, with slow titration.
- Patients had a history of using a mean of five prior anticonvulsants.
Main Results:
- 35% of patients experienced a ≥50% reduction in seizure frequency.
- Tiagabine demonstrated efficacy when combined with carbamazepine, lamotrigine, or oxcarbazepine.
- Higher tiagabine doses appeared more effective, with central nervous system side effects like dizziness being most common.
Conclusions:
- Tiagabine is effective and safe for patients with refractory epilepsy.
- Slow dose titration starting from low doses is recommended for optimal results.
- Tiagabine represents a promising option for difficult-to-treat epilepsy cases.